基因工程和生物技术的进展

Omics-Based CHO Cell Engineering – Entrance into Post-Genomic Era

Yeon-Gu Kim

Omics-Based CHO Cell Engineering – Entrance into Post-Genomic Era

Chinese hamster ovary cells (CHO) cells have been the most commonly used mammalian host for the production of therapeutic proteins since the first therapeutic protein from recombinant mammalian cells, tissue plasminogen activator (tPA, Genentech, USA) synthesized in CHO cells, was approved for clinical use in 1987. Despite the availability of various mammalian cell lines (such as BHK, HEK-293, HeLa, NS0, and PerC6), nearly 70% of all recombinant protein therapeutics produced today are made in CHO cells.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证